Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.-gliflozin: sodium-glucose co-transporter inhibitors WHO name stem
- Tested for
- T2DM (Type 2 Diabetes Mellitus) (2 trials), CKD - Chronic Kidney Disease
- Main trialPhase 4
- “The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.”In the company’s words, NCT07244003 on ClinicalTrials.gov
Other drugs for T2DM (Type 2 Diabetes Mellitus)
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up2
- 31 Dec 2027Phase 4 trial completes · ClinicalTrials.gov
- 30 Oct 2031Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 31 Dec 2027 | Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | |
| Phase 4Not yet recruiting | 30 Oct 2031 | Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026